Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study

IMPORTANCE: Abiraterone acetate is combined with prednisone, 5 mg, twice daily for metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer. Understanding the physiological effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Attard, Gerhardt, Merseburger, Axel S, Arlt, Wiebke, Sternberg, Cora N, Feyerabend, Susan, Berruti, Alfredo, Joniau, Steven, Géczi, Lajos, Lefresne, Florence, Lahaye, Marjolein, Shelby, Florence Nave, Pissart, Geneviève, Chua, Sue, Jones, Robert J, Tombal, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604092/
https://www.ncbi.nlm.nih.gov/pubmed/31246234
http://dx.doi.org/10.1001/jamaoncol.2019.1011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604092/
https://www.ncbi.nlm.nih.gov/pubmed/31246234
http://dx.doi.org/10.1001/jamaoncol.2019.1011

Ejemplares similares